The Phase III Destiny Breast-03 study 20, which randomized 524 patients with previously progressed HER2+ advanced BC, further corroborates the efficacy of T-DXd over T-DM1 in terms of PFS and shows a trend towards improved survival at 12 months. The gene discussed is ERBB2; the disease is breast cancer.